Market Cap 3.54B
Revenue (ttm) 1.36B
Net Income (ttm) 167.68M
EPS (ttm) N/A
PE Ratio 16.42
Forward PE 15.99
Profit Margin 12.32%
Debt to Equity Ratio 1.08
Volume 533,222
Avg Vol 920,056
Day's Range N/A - N/A
Shares Out 46.81M
Stochastic %K 5%
Beta 0.29
Analysts Strong Sell
Price Target $92.00

Company Profile

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLy...

Industry: Medical Devices
Sector: Healthcare
Phone: 781 848 7100
Address:
125 Summer Street, Boston, United States
ZacksResearch
ZacksResearch Jan. 15 at 4:21 PM
Is $HAE primed for growth or facing headwinds? šŸ¤” šŸ“ˆ Plasma & Hemostasis Management franchises show strong potential šŸ“‰ Dull macroeconomic scenario and fierce competition pose risks See what makes the investment case strong for $HAE šŸ‘‰ https://www.zacks.com/stock/news/2818094/is-it-apt-to-retain-hae-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2818094-body-29092&ADID=SYND_STOCKTWITS_TWEET_2_2818094_BODY_29092
0 Ā· Reply
ZacksResearch
ZacksResearch Jan. 15 at 3:21 PM
Is $HAE a hold… or a trap right now? āš ļø Haemonetics’ plasma and hemostasis franchises are showing solid growth potential, but macro headwinds and rising competition are clouding the near-term outlook. See whether HAE still earns a spot in your portfolio šŸ‘‰ https://www.zacks.com/stock/news/2818094/is-it-apt-to-retain-hae-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2818094-teaser-29090&ADID=SYND_STOCKTWITS_TWEET_2_2818094_TEASER_29090
0 Ā· Reply
Pcocc
Pcocc Jan. 13 at 5:07 PM
$HAE why is this down today?
0 Ā· Reply
smartkarma
smartkarma Jan. 12 at 6:03 PM
$HAE | Haemonetics Acquires Vivasure—Could This Be Its Next Growth Engine? "Haemonetics Corporation is making headlines with its recent strategic move to acquire Galway, Ireland-based Vivasure Medical—a developer of..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/haemonetics-acquires-vivasure-could-this-be-its-next-growth-engine
0 Ā· Reply
TechridyStocks
TechridyStocks Jan. 7 at 5:08 PM
$HAE is now bullish over $83.18 I added.
0 Ā· Reply
QuantitativeTrading_
QuantitativeTrading_ Jan. 4 at 6:03 AM
šŸ” Other targets • $VG: This is the target with the largest rising space in the current list. Technically, it is rebounding from the IPO break-through low in 2025 ($5.72). The fair value given by analysts is as high as $14.58, which implies nearly 100% potential upside, but the fluctuation is extremely high. • $MOH: Recently, stimulated by the news of Michael Burry's purchase, the stock price rose 3.28% in a single day, and the short-term momentum turned strong. In 2026, it is expected to fluctuate between $235-$415, with about 11%-30% of the repair space. • $HAE: Although the core business is slowing down, the hospital sector is growing strongly. The technical aspect is in the interval, and the consensus target price shows a steady growth potential of about 15%-22%. • $VSCO: The stock price has risen by 6% in the past 3 months, technically in a rebound trend, but it should be noted that the valuation is close to a historical high, and the upward slope may slow down.
0 Ā· Reply
JarvisFlow
JarvisFlow Dec. 17 at 3:05 PM
Mizuho has adjusted their stance on Haemonetics ( $HAE ), setting the rating to Outperform with a target price of 75 → 90.
0 Ā· Reply
JarvisFlow
JarvisFlow Dec. 15 at 6:10 PM
Baird updates rating for Haemonetics ( $HAE ) to Outperform, target set at 87 → 99.
0 Ā· Reply
JarvisFlow
JarvisFlow Dec. 15 at 11:37 AM
Needham updates rating for Haemonetics ( $HAE ) to Hold.
0 Ā· Reply
JarvisFlow
JarvisFlow Dec. 12 at 7:48 PM
JP Morgan has adjusted their stance on Haemonetics ( $HAE ), setting the rating to Neutral with a target price of 62 → 74.
0 Ā· Reply
Latest News on HAE
Haemonetics Acquires Vivasure Medical Limited

Jan 9, 2026, 6:15 AM EST - 7 days ago

Haemonetics Acquires Vivasure Medical Limited


Earn Twice The Yield You Get From Bank On HAE Stock

Dec 30, 2025, 12:50 PM EST - 17 days ago

Earn Twice The Yield You Get From Bank On HAE Stock


Top 2 Health Care Stocks You May Want To Dump This Month

Dec 2, 2025, 9:01 AM EST - 6 weeks ago

Top 2 Health Care Stocks You May Want To Dump This Month

EXAS


Haemonetics Is Still Undervalued, Even After The Rally

Nov 7, 2025, 10:41 AM EST - 2 months ago

Haemonetics Is Still Undervalued, Even After The Rally


Haemonetics Corporation (HAE) Q2 2026 Earnings Call Transcript

Nov 7, 2025, 3:26 AM EST - 2 months ago

Haemonetics Corporation (HAE) Q2 2026 Earnings Call Transcript


Haemonetics Corporation (HAE) Q1 2026 Earnings Call Transcript

Aug 9, 2025, 10:53 PM EDT - 5 months ago

Haemonetics Corporation (HAE) Q1 2026 Earnings Call Transcript


Haemonetics Corporation (HAE) Q4 2025 Earnings Call Transcript

May 10, 2025, 1:05 PM EDT - 8 months ago

Haemonetics Corporation (HAE) Q4 2025 Earnings Call Transcript


Haemonetics Announces Executive Leadership Updates

Mar 3, 2025, 4:10 PM EST - 11 months ago

Haemonetics Announces Executive Leadership Updates


Haemonetics Corporation (HAE) Q4 2024 Earnings Call Transcript

May 10, 2024, 12:25 AM EDT - 1 year ago

Haemonetics Corporation (HAE) Q4 2024 Earnings Call Transcript


ZacksResearch
ZacksResearch Jan. 15 at 4:21 PM
Is $HAE primed for growth or facing headwinds? šŸ¤” šŸ“ˆ Plasma & Hemostasis Management franchises show strong potential šŸ“‰ Dull macroeconomic scenario and fierce competition pose risks See what makes the investment case strong for $HAE šŸ‘‰ https://www.zacks.com/stock/news/2818094/is-it-apt-to-retain-hae-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2818094-body-29092&ADID=SYND_STOCKTWITS_TWEET_2_2818094_BODY_29092
0 Ā· Reply
ZacksResearch
ZacksResearch Jan. 15 at 3:21 PM
Is $HAE a hold… or a trap right now? āš ļø Haemonetics’ plasma and hemostasis franchises are showing solid growth potential, but macro headwinds and rising competition are clouding the near-term outlook. See whether HAE still earns a spot in your portfolio šŸ‘‰ https://www.zacks.com/stock/news/2818094/is-it-apt-to-retain-hae-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2818094-teaser-29090&ADID=SYND_STOCKTWITS_TWEET_2_2818094_TEASER_29090
0 Ā· Reply
Pcocc
Pcocc Jan. 13 at 5:07 PM
$HAE why is this down today?
0 Ā· Reply
smartkarma
smartkarma Jan. 12 at 6:03 PM
$HAE | Haemonetics Acquires Vivasure—Could This Be Its Next Growth Engine? "Haemonetics Corporation is making headlines with its recent strategic move to acquire Galway, Ireland-based Vivasure Medical—a developer of..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/haemonetics-acquires-vivasure-could-this-be-its-next-growth-engine
0 Ā· Reply
TechridyStocks
TechridyStocks Jan. 7 at 5:08 PM
$HAE is now bullish over $83.18 I added.
0 Ā· Reply
QuantitativeTrading_
QuantitativeTrading_ Jan. 4 at 6:03 AM
šŸ” Other targets • $VG: This is the target with the largest rising space in the current list. Technically, it is rebounding from the IPO break-through low in 2025 ($5.72). The fair value given by analysts is as high as $14.58, which implies nearly 100% potential upside, but the fluctuation is extremely high. • $MOH: Recently, stimulated by the news of Michael Burry's purchase, the stock price rose 3.28% in a single day, and the short-term momentum turned strong. In 2026, it is expected to fluctuate between $235-$415, with about 11%-30% of the repair space. • $HAE: Although the core business is slowing down, the hospital sector is growing strongly. The technical aspect is in the interval, and the consensus target price shows a steady growth potential of about 15%-22%. • $VSCO: The stock price has risen by 6% in the past 3 months, technically in a rebound trend, but it should be noted that the valuation is close to a historical high, and the upward slope may slow down.
0 Ā· Reply
JarvisFlow
JarvisFlow Dec. 17 at 3:05 PM
Mizuho has adjusted their stance on Haemonetics ( $HAE ), setting the rating to Outperform with a target price of 75 → 90.
0 Ā· Reply
JarvisFlow
JarvisFlow Dec. 15 at 6:10 PM
Baird updates rating for Haemonetics ( $HAE ) to Outperform, target set at 87 → 99.
0 Ā· Reply
JarvisFlow
JarvisFlow Dec. 15 at 11:37 AM
Needham updates rating for Haemonetics ( $HAE ) to Hold.
0 Ā· Reply
JarvisFlow
JarvisFlow Dec. 12 at 7:48 PM
JP Morgan has adjusted their stance on Haemonetics ( $HAE ), setting the rating to Neutral with a target price of 62 → 74.
0 Ā· Reply
ZacksResearch
ZacksResearch Dec. 12 at 12:12 PM
HAE might be setting up for a quiet comeback — here’s what stands out. $HAE is seeing a Hospital rebound and rising NexSys PCS adoption, which boosts growth prospects even as FX and solvency pressures linger. That mix makes the hold-or-sell debate a lot more interesting right now. Full breakdown here šŸ‘‰ https://www.zacks.com/stock/news/2803441/is-it-apt-to-retain-haemonetics-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2803441-teaser-24535&ADID=SYND_STOCKTWITS_TWEET_2_2803441_TEASER_24535
0 Ā· Reply
ZacksResearch
ZacksResearch Dec. 12 at 11:12 AM
$HAE’s Hospital business is back on the growth track! šŸš€ With a 5% revenue boost in the Hospital business and 12% sales growth in Blood Management Technologies, Haemonetics is positioned to capitalize on dynamic market conditions. However, watch out for foreign exchange impacts and solvency concerns. Opportunity assessment here šŸ‘‰ https://www.zacks.com/stock/news/2803441/is-it-apt-to-retain-haemonetics-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2803441-body-24534&ADID=SYND_STOCKTWITS_TWEET_2_2803441_BODY_24534
0 Ā· Reply
JarvisFlow
JarvisFlow Dec. 11 at 1:55 PM
Citigroup updates rating for Haemonetics ( $HAE ) to Neutral, target set at 77 → 88.
0 Ā· Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 7:57 PM
$HAE Current Stock Price: $86.67 Contracts to trade: $85 HAE Dec 19 2025 Call Entry: $0.15 Exit: $0.21 ROI: 42% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 Ā· Reply
stockanalysis_
stockanalysis_ Dec. 5 at 1:07 AM
Overbought Stocks: $MAGH $SND $HAE $EXAS $CDTX View the entire list here: https://stockanalysis.com/list/overbought-stocks/?ref=saveontrading
0 Ā· Reply
Estimize
Estimize Dec. 1 at 2:03 PM
Wall St is expecting 1.25 EPS for $HAE Q3 [Reporting 02/10 BMO] http://www.estimize.com/intro/hae?chart=historical&metric_name=eps&utm_cont
0 Ā· Reply
Cutlass
Cutlass Nov. 28 at 3:12 PM
$HAE Out for now - solid run from 48 šŸ’„
1 Ā· Reply
Cutlass
Cutlass Nov. 25 at 3:37 PM
$HAE Trim a bit 81.25 and every dollar up šŸ‘€
0 Ā· Reply
Cutlass
Cutlass Nov. 24 at 5:43 PM
$HAE Trim a tad at 80 šŸŽ
0 Ā· Reply
stockanalysis_
stockanalysis_ Nov. 22 at 4:00 PM
Overbought Stocks: $EXAS $HAE $FRGE $CDTX $BACC.X Bookmark this page: https://stockanalysis.com/list/overbought-stocks/?ref=saveontrading
0 Ā· Reply
FlaMeZ907
FlaMeZ907 Nov. 21 at 6:26 PM
$HAE What's up with all these crappy bio pharma companies going up in a straight line? šŸ‘©šŸ»ā€āš•ļø
3 Ā· Reply
Cutlass
Cutlass Nov. 21 at 4:08 PM
$HAE Trim 77 šŸŽ
0 Ā· Reply